Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 66.45% is 31% above its 5-year average of 50.60%, near the high end of its 5-year range (9.84%–74.74%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.60% below its 12-month average of 69.65%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 66.45%.
DEBT TO ASSETS RATIO
66.45%
DEBT TO ASSETS RATIO AVG TTM
69.65%
DEBT TO ASSETS RATIO AVG 3Y
62.81%
DEBT TO ASSETS RATIO AVG 5Y
50.60%
DEBT TO ASSETS RATIO AVG 10Y
46.03%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-4.60%
CURRENT VS 3Y AVG
+5.78%
CURRENT VS 5Y AVG
+31.33%
CURRENT VS 10Y AVG
+44.34%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 536 covered companies
CURRENT VS SECTOR MEDIAN
+66346.80%
vs the sector median at left
Evolus, Inc.
Market Cap
$480.08M
Debt to Assets Ratio
66.45%
TTM Avg
69.65%
3Y Avg
62.81%
5Y Avg
50.60%
Market Cap
$489.55M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$465.00M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$460.70M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $480.08M | 66.45% | 69.65% | 62.81% | 50.60% |
| Cerus Corporation (CERS)vs › | $479.63M | 0.37% | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $477.45M | 0.01% | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $473.72M | 0.66% | N/A | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $489.55M | 0.00% | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $491.93M | 0.33% | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $465.00M | 0.03% | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $463.63M | 0.03% | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $460.70M | 0.00% | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $451.17M | 0.25% | N/A | N/A | N/A |
Debt/Assets
66.4%
Debt/Equity
N/A
Current Ratio
1.70
Interest Coverage
-1.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 66.45% |
| 2026-03-31 | 74.74% |
| 2025-12-31 | 68.62% |
| 2025-09-30 | 70.73% |
| 2025-06-30 | 67.70% |
| 2025-03-31 | 61.02% |
| 2024-12-31 | 55.89% |
| 2024-09-30 | 56.56% |
| 2024-06-30 | 54.22% |
| 2024-03-31 | 56.00% |
| 2023-12-31 | 66.96% |
| 2023-09-30 | 60.39% |
| 2023-06-30 | 57.30% |
| 2023-03-31 | 46.38% |
| 2022-12-31 | 41.81% |
| 2022-09-30 | 38.66% |
| 2022-06-30 | 35.36% |
| 2022-03-31 | 33.84% |
| 2021-12-31 | 29.03% |
| 2021-09-30 | 11.01% |
| 2021-06-30 | 9.84% |
| 2021-03-31 | 14.96% |
| 2020-12-31 | 66.16% |
| 2020-09-30 | 63.72% |
| 2020-06-30 | 50.05% |
| 2020-03-31 | 45.28% |
| 2019-12-31 | 40.15% |
| 2019-09-30 | 52.59% |
| 2019-06-30 | 47.07% |
| 2019-03-31 | 40.98% |
| 2018-12-31 | 9.84% |
| 2018-09-30 | 9.16% |
| 2018-06-30 | 13.51% |
| 2018-03-31 | 12.68% |
| 2017-12-31 | 138.82% |
| 2017-09-30 | 51.44% |
| 2017-06-30 | 130.71% |
| 2016-12-31 | 77.11% |
